ExelixisEXEL
- Legal name
- Exelixis, Inc.
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- Nasdaq
Stock Price $EXEL
Latest filings
You are here#56 of 59 in Healthcare by market cap
Area = market cap · hover a tile to read it
EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 16, 2016
- 10-K · Feb 29, 2016
- 8-K · Feb 29, 2016
- 10-Q · May 4, 2016
- 8-K · May 4, 2016
- 8-K · May 26, 2016
- 10-Q · Aug 3, 2016
- 8-K · Aug 3, 2016
- 8-K · Aug 9, 2016
- 8-K · Aug 22, 2016
- 8-K · Sep 26, 2016
- 10-Q/A · Sep 30, 2016
- 8-K · Nov 3, 2016
- 10-Q · Nov 3, 2016
- 8-K · Nov 22, 2016
- 8-K · Dec 21, 2016
- 8-K · Jan 31, 2017
- 8-K · Feb 27, 2017
- 10-K · Feb 27, 2017
- 10-Q · May 1, 2017
- 8-K · May 1, 2017
- 8-K · May 2, 2017
- 8-K · May 11, 2017
- 8-K · May 25, 2017
- 10-Q/A · Jul 14, 2017
- 8-K · Jul 20, 2017
- 8-K · Aug 2, 2017
- 10-Q · Aug 2, 2017
- 8-K/A · Sep 8, 2017
- 8-K · Sep 8, 2017
- 8-K · Nov 1, 2017
- 10-Q · Nov 1, 2017
- 8-K · Feb 16, 2018
- 10-K · Feb 26, 2018
- 8-K · Feb 26, 2018
- 8-K · Apr 9, 2018
- 8-K · May 2, 2018
- 10-Q · May 2, 2018
- 8-K · May 24, 2018
- 10-Q · Aug 1, 2018
- 8-K · Aug 1, 2018
- 10-Q · Nov 1, 2018
- 8-K · Nov 1, 2018
- 8-K · Feb 12, 2019
- 8-K · Feb 21, 2019
- 10-K · Feb 22, 2019
- 8-K · Mar 5, 2019
- 8-K · Apr 5, 2019
- 8-K · Apr 25, 2019
- 8-K · May 1, 2019
- 10-Q · May 1, 2019
- 8-K · May 23, 2019
- 8-K · Jun 20, 2019
- 10-Q · Jul 31, 2019
- 8-K · Jul 31, 2019
- 8-K · Sep 26, 2019
- 8-K · Oct 7, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Dec 19, 2019
- 8-K · Jan 13, 2020
- 8-K · Feb 20, 2020
- 10-K · Feb 25, 2020
- 8-K · Feb 25, 2020
- 8-K · Mar 2, 2020
- 8-K · Apr 20, 2020
- 8-K · May 5, 2020
- 10-Q · May 5, 2020
- 8-K · May 12, 2020
- 8-K · May 22, 2020
- 8-K · Aug 6, 2020
- 10-Q · Aug 6, 2020
- 8-K · Nov 5, 2020
- 10-Q · Nov 5, 2020
- 8-K · Jan 11, 2021
- 8-K · Feb 5, 2021
- 8-K · Feb 10, 2021
- 10-K · Feb 11, 2021
- 8-K · Mar 3, 2021
- 8-K · Mar 5, 2021
- 10-Q · May 6, 2021
- 8-K · May 6, 2021
- 8-K · May 11, 2021
- 8-K · May 27, 2021
- 8-K · Jun 21, 2021
- 8-K · Jun 21, 2021
- 8-K · Aug 5, 2021
- 10-Q · Aug 5, 2021
- 8-K · Nov 2, 2021
- 10-Q · Nov 2, 2021
- 8-K · Dec 17, 2021
- 8-K · Jan 10, 2022
- 8-K · Feb 17, 2022
- 10-K · Feb 18, 2022
- 8-K · Feb 23, 2022
- 8-K · Apr 13, 2022
- 10-Q · May 10, 2022
- 8-K · May 10, 2022
- 8-K · May 27, 2022
- 8-K · Jul 19, 2022
- 8-K · Aug 9, 2022
- 10-Q · Aug 9, 2022
- 8-K · Sep 2, 2022
- 10-Q · Nov 1, 2022
- 8-K · Nov 1, 2022
- 8-K · Dec 15, 2022
- 8-K · Jan 9, 2023
- 10-K · Feb 7, 2023
- 8-K · Feb 7, 2023
- 8-K · Mar 20, 2023
- 8-K · Mar 22, 2023
- 8-K · Apr 13, 2023
- 8-K · May 8, 2023
- 10-Q · May 9, 2023
- 8-K · May 9, 2023
- 8-K · Jun 5, 2023
- 8-K · Jul 24, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 1, 2023
- 8-K · Aug 23, 2023
- 8-K · Sep 19, 2023
- 10-Q · Nov 1, 2023
- 8-K · Nov 1, 2023
- 8-K · Dec 20, 2023
- 8-K · Jan 8, 2024
- 10-K · Feb 6, 2024
- 8-K · Feb 6, 2024
- 8-K · Mar 29, 2024
- 8-K · Apr 30, 2024
- 10-Q · Apr 30, 2024
- 8-K · May 10, 2024
- 8-K · May 20, 2024
- 8-K · Jun 3, 2024
- 8-K · Aug 6, 2024
- 10-Q · Aug 6, 2024
- 8-K · Oct 15, 2024
- 8-K · Oct 15, 2024
- 10-Q · Oct 29, 2024
- 8-K · Oct 29, 2024
- 8-K · Jan 13, 2025
- 8-K · Feb 11, 2025
- 10-K · Feb 11, 2025
- 8-K · Feb 21, 2025
- 8-K · Mar 31, 2025
- 10-Q · May 13, 2025
- 8-K · May 13, 2025
- 8-K · Jun 2, 2025
- 8-K · Jul 28, 2025
- 10-Q · Jul 28, 2025
- 8-K · Aug 29, 2025
- 10-Q · Nov 4, 2025
- 8-K · Nov 4, 2025
- 8-K · Nov 7, 2025
- 8-K · Jan 12, 2026
- 8-K · Feb 10, 2026
- 10-K · Feb 10, 2026
- 10-Q · May 5, 2026
- 8-K · May 5, 2026
- 8-K · May 29, 2026
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026
- 8-K · Aug 31, 2026
- 8-K · Sep 11, 2026
- 8-K · Oct 29, 2026
- 10-Q · Oct 29, 2026
01—Key figures
Revenue Trend
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2026
- $2.32B
1 older move runs past ±150% (largest +1117.3%); point at, tap or drag across the bars to read one.
Latest bar from 10-KFY2026Click a bar to open its SEC filingTap a bar to open its SEC filing
View full history →All EXEL Financial Metrics57 metrics
Income Statement16
Balance Sheet24
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Accrued Liabilities
- Short-Term Debt
- Deferred Revenue
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Total L&E
- Shares Outstanding
Cash Flow13
02—Overview
Exelixis Financial Overview 2021–2026
Updated Nov 5, 2026Exelixis's net income more than tripled between FY2021 and FY2025, rising from $231.1 million to $782.6 milliona, while revenue grew only 62%. That gap is the story. Net margin roughly doubled, from about 16% to 34%. The core thesis is that CABOMETYX now converts sales into profit far more efficiently, and buybacks have amplified the per-share result, but the whole structure rests on one drug facing patent expiry.
Revenue grew from $1,435.0 million in FY2021 to $2,320.1 millionb in FY2025. Net product revenues reached $2,122.8 million in FY2025, helped by a 16% rise in CABOMETYX units sold. Collaboration revenue fell to $197.3 million from $359.3 million as the 2024 Ipsen milestone rolled off, yet net income still climbed 50% from $521.3 million. R&D spending fell to $825.0 million from $910.4 million. Operating cash flow hit $884.3 million, and the company spent $1,159.7 million repurchasing 30.2 million shares. Year-end cash slipped to $1.66 billion from $1.75 billion.
The market priced this at $43.58c per share at the close on January 1, 2026, or 15.7x earnings, for a market cap of $11.4 billion. That is a modest multiple for earnings that tripled. The discount reflects the risk: the composition-of-matter patent expires in August 2026, and a consolidated generic-challenge trial is set for November 2, 2026.
Recent Developments (Q2 and Q3 2027)
Revenue rose from $628.7 million in Q2 2026 to $658.7 milliond in Q3 2026, and net income climbed from $212.1 million to $218.1 million. Growth in Q3 2026 came from a 6% rise in CABOMETYX units and a 5% higher net price. Management lowered FY2026 revenue guidance to $2.500–$2.550 billion in Q2. The FDA then extended the zanzalintinib review to March 3, 2027. The Federal Circuit upheld three CABOMETYX patents against MSN, blocking generic approval before January 15, 2030. Azurity settled, with a license starting December 1, 2030. Handa won full approval of a 505(b)(2) product.
Bull case: patent wins push generic entry out years, and EPS of $0.85e grew from $0.69. Bear case: guidance was cut, the zanzalintinib decision slipped, and buybacks cut cash to $1.4 billion. The stock traded at 23.8x earnings as of the Q3 2026 report date (October 28, 2026), up from 15.7x, not today's multiple.
What to watch: STELLAR-304 nccRCC topline results in Q1 2027; the November 2026 trial on the '039 patent
03—Filings
Recent SEC Filings
- 8-KExelixis 8-K Report, Financial Results (Oct 29, 2026)Exelixis, Inc. (Nasdaq: EXEL) reported third-quarter 2026 financial results on October 29, 2026, furnishing a press release as Exhibit 99.1. Total revenues were $658.7 million, up from $597.8 million a year earlier, driven by net product revenues of $604.9 million (compared with $542.9 million), which the company attributed to higher sales volume and a higher average net selling price. Collaboration revenues were $53.8 million, versus $54.8 million. GAAP net income was $218.1 million, or $0.85 per diluted share, compared with $193.6 million, or $0.69 per diluted share, a year earlier. Non-GAAP diluted EPS, which excludes stock-based compensation net of tax, was $0.94. Research and development expenses rose to $209.5 million and selling, general and administrative expenses rose to $154.6 million. The company updated its 2026 guidance, lowering the expected effective tax rate to 16% to 18% from 21% to 23%, while raising cost of goods sold to approximately 4% of net product revenues from 3.5% to 4.5%. Total revenue guidance ($2.500 billion to $2.550 billion) and net product revenue guidance ($2.300 billion to $2.350 billion) were unchanged and do not reflect any potential zanzalintinib launch. The FDA is reviewing the zanzalintinib NDA for previously treated metastatic colorectal cancer in combination with atezolizumab, with a PDUFA target action date of March 3, 2027 after a three-month extension. The company also disclosed a $750 million stock repurchase authorization from May 2026, under which it had bought back $402.1 million at an average price of $54.03 per share by quarter end. The filing also reports a settlement and license agreement with Azurity Pharmaceuticals, entered October 28, 2026, granting a license beginning December 1, 2030, and a Federal Circuit decision in August 2026 upholding patents against MSN Laboratories, which sets an effective date for any MSN ANDA approval of no earlier than January 15, 2030. Topline results from the phase 3 STELLAR-304 trial are expected in the first quarter of 2027.
- 8-KExelixis 8-K Report, Corporate Update (Sep 11, 2026)Exelixis, Inc. filed this Form 8-K to report that on September 10, 2026, the U.S. Food and Drug Administration notified the company that it had extended the review period for its new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer, by three months. The extension followed an FDA information request to which Exelixis responded by submitting updated safety and efficacy data, which the FDA has deemed a major amendment. The revised Prescription Drug User Fee Act (PDUFA) action date is now March 3, 2027. The filing does not state the original action date, the specific content of the updated data, or the outcome of the review. Investors should note that the timeline for a potential approval decision on this indication has been pushed back by three months. The filing is a brief Item 8.01 (Other Events) disclosure signed by Brenda J. Hefti, Senior Vice President and General Counsel, on September 11, 2026.
- 8-KExelixis 8-K Report, Corporate Update (Aug 31, 2026)Exelixis announced that the U.S. Court of Appeals for the Federal Circuit affirmed the District of Delaware's judgment in Exelixis, Inc. v. MSN Laboratories Private Limited et al. (Appeal No. 25-1236) that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid. The Court of Appeals also dismissed as moot MSN's appeal regarding the validity of U.S. Patent No. 11,298,349, which expires on February 10, 2032, and vacated the portion of the district court's decision addressing that patent. Based on the appellate opinion, the effective date of any final FDA approval of MSN's ANDA will not be earlier than January 15, 2030, the expiration date of the three upheld patents. The filing states this is subject to further appellate proceedings, applicable regulatory exclusivity, and the outcome of separate litigation over U.S. Patent No. 12,128,039, which expires in February 2032. Trial in that litigation is currently scheduled to begin in November 2026. The filing is a Form 8-K under Item 8.01 (Other Events) and includes forward-looking statements about the timing of any MSN generic launch in the U.S., pending litigation outcomes, and regulatory exclusivity, which the company notes are subject to the risks described in its Form 10-K and Form 10-Q filings.
- 8-KExelixis 8-K Report, Financial Results (Aug 5, 2026)Exelixis, Inc. reported financial results for the second quarter ended June 30, 2026 (the filing's fiscal quarter ended July 3, 2026) in a press release furnished as Exhibit 99.1 to this Form 8-K. Total revenues were $628.7 million, up from $568.3 million a year earlier, driven by net product revenues of $573.0 million (versus $520.0 million), which the company attributed primarily to higher sales volume. GAAP net income was $212.1 million, or $0.82 per diluted share, compared with $184.8 million, or $0.65 per diluted share, in the prior-year quarter. Non-GAAP net income was $237.1 million, or $0.91 per diluted share. Research and development expenses rose to $212.0 million and SG&A expenses rose to $147.6 million. Exelixis lowered its FY 2026 guidance. Total revenues are now expected at $2.500 billion to $2.550 billion (previously $2.525 billion to $2.625 billion), net product revenues at $2.300 billion to $2.350 billion (previously $2.325 billion to $2.425 billion), and R&D expenses at $825 million to $875 million (previously $875 million to $925 million). Guidance excludes any revenue from a potential launch of zanzalintinib in metastatic colorectal cancer. The FDA is reviewing the zanzalintinib NDA, with a PDUFA target action date of December 3, 2026. The company repurchased $311.6 million of stock in the quarter at an average price of $47.85 per share, completed the $750 million October 2025 repurchase program, and began executing a new $750 million program authorized in May 2026 that runs through December 31, 2027. The filing also outlines pipeline milestones, including topline STELLAR-304 results expected in the second half of 2026 and initiation of the STELLAR-316 pivotal trial in mid-2026.
- 8-KExelixis 8-K Report, Executive Changes (May 29, 2026)Exelixis, Inc. reported results from its 2026 Annual Meeting of Stockholders, held via live webcast on May 26, 2026. At the meeting, stockholders approved the amendment and restatement of the Exelixis, Inc. 2017 Equity Incentive Plan (the 2017 Plan), which became effective immediately upon approval. The filing incorporates by reference the plan summary in "Proposal 3" of the definitive proxy statement filed April 15, 2026, and the full plan text is filed as Exhibit 10.1. Stockholders elected all 11 nominated directors to serve until the 2027 annual meeting. Each nominee received more votes FOR than AGAINST, though the AGAINST votes were notably higher for some nominees, such as Maria C. Freire, Ph.D. (180,367,648 FOR and 26,067,310 AGAINST) and Stelios Papadopoulos, Ph.D. (198,500,120 FOR and 7,922,275 AGAINST). Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending January 1, 2027, with 222,343,120 votes FOR and 6,485,691 AGAINST. Stockholders approved the 2017 Plan with 196,926,657 votes FOR and 9,343,837 AGAINST. On the advisory Say on Pay proposal, stockholders approved the compensation of named executive officers, with 163,104,135 votes FOR and 43,156,553 AGAINST, a higher level of opposition than on the other proposals.
04—See also
Related Companies
Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.